Changing the selectivity profile–from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue , 2016, Pages 89-97

  Maiwald, Alexander ^a   Hammami, Maya ^a   Wagner, Sebastian ^a   Heine, Andreas ^a   Klebe, Gerhard ^a   Steinmetzer, Torsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Benzamidines; matriptase; protease inhibition; trypsin; X ray structure

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBENE; MATRIPTASE; PHENYLALANINE; THROMBIN; THROMBIN INHIBITOR; TRYPSIN; TYROSINE; TYROSYLALANINE 4 AMIDINOBENZYLAMIDE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; SERINE PROTEINASE;

ARTICLE; BIOCHEMICAL ANALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; INHIBITION CONSTANT; MOLECULAR MODEL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FACTOR XA; FACTOR XA INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 84966707964     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2016.1172574     Document Type: Article

References (54)

1. Antalis TM, Bugge TH, Wu Q., Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011;99:1–50
2. Miller GS, List K., The matriptase-prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res 2013;351:245–53
3. List K, Haudenschild CC, Szabo R, et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002;21:3765–79
4. Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet 2007;80:467–77
5. List K, Currie B, Scharschmidt TC, et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J Biol Chem 2007;282:36714–23
6. Buzza MS, Netzel-Arnett S, Shea-Donohue T, et al. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 2010;107:4200–5
7. Netzel-Arnett S, Buzza MS, Shea-Donohue T, et al. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis 2012;18:1303–14
8. Uhland K., Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968–78
9. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333–42
10. Lee SL, Dickson RB, Lin CY., Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720–5
11. Suzuki M, Kobayashi H, Kanayama N, et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004;279:14899–908
12. Comoglio PM, Giordano S, Trusolino L., Drug development of MET inhibitors:targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504–16
13. Trusolino L, Comoglio PM., Scatter-factor and semaphorin receptors:cell signalling for invasive growth. Nat Rev Cancer 2002;2:289–300
14. Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395–402
15. Milner JM, Patel A, Davidson RK, et al. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum 2010;62:1955–66
16. Chen CJ, Wu BY, Tsao PI, et al. Increased matriptase zymogen activation in inflammatory skin disorders. Am J Physiol Cell Physiol 2011;300:C406–15
17. Hamilton BS, Gludish DW, Whittaker GR., Cleavage activation of the human-adapted influenza virus subtypes by matriptase reveals both subtype and strain specificities. J Virol 2012;86:10579–86
18. Baron J, Tarnow C, Mayoli-Nüssle D, et al. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J Virol 2013;87:1811–20
19. Galkin AV, Mullen L, Fox WD, et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004;61:228–35
20. Steinmetzer T, Schweinitz A, Stürzebecher A, et al. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006;49:4116–26
21. Uhland K, Siphos B, Arkona C, et al. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int J Oncol 2009;35:347–57
22. Zoratti GL, Tanabe LM, Varela FA, et al. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. Nat Commun 2015;6:6776
23. Colombo E, Desilets A, Duchene D, et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med Chem Lett 2012;3:530–4
24. Han Z, Harris PK, Jones DE, et al. Inhibitors of HGFA, matriptase, and hepsin serine proteases:a nonkinase strategy to block cell signaling in cancer. ACS Med Chem Lett 2014;5:1219–24
25. Goswami R, Mukherjee S, Wohlfahrt G, et al. Discovery of pyridyl bis(oxy)dibenzimidamide derivatives as selective matriptase inhibitors. ACS Med Chem Lett 2013;4:1152–7
26. Goswami R, Wohlfahrt G, Mukherjee S, et al. Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach. Bioorg Med Chem Lett 2015;25:616–20
27. Sisay MT, Steinmetzer T, Stirnberg M, et al. Identification of the first low-molecular-weight inhibitors of matriptase-2. J Med Chem 2010;53:5523–35
28. Lila C, Gloanec P, Cadet L, et al. Large scale preparation of protected 4-aminomethylbenzamidine. application to the synthesis of the thrombin inhibitor, Melagatran. Chem Commun 1997;28:4419–29
29. Gustafsson D, Bylund R, Antonsson T, et al. A new oral anticoagulant:the 50-year challenge. Nat Rev Drug Discov 2004;3:649–59
30. Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613–22
31. Stürzebecher A, Dönnecke D, Schweinitz A, et al. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue:part 2. ChemMedChem 2007;2:1043–53
32. Kadono S, Sakamoto A, Kikuchi Y, et al. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. Biochem Biophys Res Commun 2005;327:589–96
33. Saupe SM, Steinmetzer T., A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem 2012;55:1171–80
34. Hellstern P, Stürzebecher U, Wuchold B, et al. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost 2007;5:2119–26
35. Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010;53:1067–75
36. Kauer J., P-Benzoyl-L-phenylalanine, a new photoreactive amino acid. Photolabeling of calmodulin with a synthetic calmodulin-binding peptide. J Biol Chem 1986;261:10695–700
37. Meyer D, Sielaff F, Hammami M, et al. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J 2013;452:331–43
38. Walsmann P., On the purification of thrombin preparations. Pharmazie 1968;23:401–2
39. Hammami M, Rühmann E, Maurer E, et al. New 3-amidinophenylalanine-derived inhibitors of matriptase. MedChemComm 2012;3:807–13
40. Dixon M., The determination of enzyme inhibitor constants. Biochem J 1953;55:170–1
41. Otwinowski Z, Minor W., Processing of X-ray diffraction data collected in oscillation mode. Meth Enzymol 1997;276:307–26
42. Brandt T, Holzmann N, Muley L, et al. Congeneric but still distinct:how closely related trypsin ligands exhibit different thermodynamic and structural properties. J Mol Biol 2011;405:1170–87
43. Collaborative Computational Project Number 4.The CCP4 suite:programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760–3
44. Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX:a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213–21
45. Emsley P, Cowtan K., Coot:model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126–32
46. Bode W, Mayr I, Baumann U, et al. The refined 1.9 A crystal structure of human alpha-thrombin:interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989;8:3467–75
47. Tziridis A, Rauh D, Neumann P, et al. Correlating structure and ligand affinity in drug discovery:a cautionary tale involving second shell residues. Biol Chem 2014;395:891–903
48. Chemical Computing Group. MOE, version 2014.9, 32 bit. Montreal, Canada
49. Sielaff F, Böttcher-Friebertshäuser E, Meyer D, et al. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett 2011;21:4860–4
50. Biela A, Sielaff F, Terwesten F, et al. Ligand binding stepwise disrupts water network in thrombin:enthalpic and entropic changes reveal classical hydrophobic effect. J Med Chem 2012;55:6094–110
51. Böttcher-Friebertshäuser E, Freuer C, Sielaff F, et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010;84:5605–14
52. Schweinitz A, Stürzebecher A, Stürzebecher U, et al. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue:part 1. Med Chem 2006;2:349–61
53. Tucker TJ, Lumma WC, Mulichak AM, et al. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997;40:830–2
54. Steinmetzer T, Dönnecke D, Korsonewski M, et al. Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors. Bioorg Med Chem Lett 2009;19:67–73